Literature DB >> 30122422

CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient.

Daniela Benati1, Francesca Miselli1, Fabienne Cocchiarella1, Clarissa Patrizi1, Marta Carretero2, Samantha Baldassarri1, Virginia Ammendola3, Cristina Has4, Stefano Colloca3, Marcela Del Rio2, Fernando Larcher2, Alessandra Recchia5.   

Abstract

Deficiency of basement membrane heterotrimeric laminin 332 component, coded by LAMA3, LAMB3, and LAMC2 genes, causes junctional epidermolysis bullosa (JEB), a severe skin adhesion defect. Herein, we report the first application of CRISPR/Cas9-mediated homology direct repair (HDR) to in situ restore LAMB3 expression in JEB keratinocytes in vitro and in immunodeficient mice transplanted with genetically corrected skin equivalents. We packaged an adenovector carrying Cas9/guide RNA (gRNA) tailored to the intron 2 of LAMB3 gene and an integration defective lentiviral vector bearing a promoterless quasi-complete LAMB3 cDNA downstream a splice acceptor site and flanked by homology arms. Upon genuine HDR, we exploited the in vitro adhesion advantage of laminin 332 production to positively select LAMB3-expressing keratinocytes. HDR and restored laminin 332 expression were evaluated at single-cell level. Notably, monoallelic-targeted integration of LAMB3 cDNA was sufficient to in vitro recapitulate the adhesive property, the colony formation typical of normal keratinocytes, as well as their cell growth. Grafting of genetically corrected skin equivalents onto immunodeficient mice showed a completely restored dermal-epidermal junction. This study provides evidence for efficient CRISPR/Cas9-mediated in situ restoration of LAMB3 expression, paving the way for ex vivo clinical application of this strategy to laminin 332 deficiency.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR/Cas9 gene editing; LAMB3 mutations; adhesion advantage

Mesh:

Substances:

Year:  2018        PMID: 30122422      PMCID: PMC6224783          DOI: 10.1016/j.ymthe.2018.07.024

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

1.  In vivo genome editing of the albumin locus as a platform for protein replacement therapy.

Authors:  Rajiv Sharma; Xavier M Anguela; Yannick Doyon; Thomas Wechsler; Russell C DeKelver; Scott Sproul; David E Paschon; Jeffrey C Miller; Robert J Davidson; David Shivak; Shangzhen Zhou; Julianne Rieders; Philip D Gregory; Michael C Holmes; Edward J Rebar; Katherine A High
Journal:  Blood       Date:  2015-08-21       Impact factor: 22.113

2.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

3.  TALEN-based gene correction for epidermolysis bullosa.

Authors:  Mark J Osborn; Colby G Starker; Amber N McElroy; Beau R Webber; Megan J Riddle; Lily Xia; Anthony P DeFeo; Richard Gabriel; Manfred Schmidt; Christof von Kalle; Daniel F Carlson; Morgan L Maeder; J Keith Joung; John E Wagner; Daniel F Voytas; Bruce R Blazar; Jakub Tolar
Journal:  Mol Ther       Date:  2013-04-02       Impact factor: 11.454

4.  An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.

Authors:  Daniele Catalucci; Elisabetta Sporeno; Agostino Cirillo; Gennaro Ciliberto; Alfredo Nicosia; Stefano Colloca
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.

Authors:  Maria Carmela Latella; Fabienne Cocchiarella; Laura De Rosa; Giandomenico Turchiano; Manuel A F V Gonçalves; Fernando Larcher; Michele De Luca; Alessandra Recchia
Journal:  J Invest Dermatol       Date:  2016-12-24       Impact factor: 8.551

6.  Laminin-5 mutational analysis in an Italian cohort of patients with junctional epidermolysis bullosa.

Authors:  Patrizia Posteraro; Naomi De Luca; Guerrino Meneguzzi; May El Hachem; Corrado Angelo; Tommaso Gobello; Gianluca Tadini; Giovanna Zambruno; Daniele Castiglia
Journal:  J Invest Dermatol       Date:  2004-10       Impact factor: 8.551

7.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

8.  GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases.

Authors:  Shengdar Q Tsai; Zongli Zheng; Nhu T Nguyen; Matthew Liebers; Ved V Topkar; Vishal Thapar; Nicolas Wyvekens; Cyd Khayter; A John Iafrate; Long P Le; Martin J Aryee; J Keith Joung
Journal:  Nat Biotechnol       Date:  2014-12-16       Impact factor: 54.908

9.  COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Stefan Hainzl; Patricia Peking; Thomas Kocher; Eva M Murauer; Fernando Larcher; Marcela Del Rio; Blanca Duarte; Markus Steiner; Alfred Klausegger; Johann W Bauer; Julia Reichelt; Ulrich Koller
Journal:  Mol Ther       Date:  2017-07-13       Impact factor: 11.454

10.  Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes.

Authors:  Cristina Chamorro; Angeles Mencía; David Almarza; Blanca Duarte; Hildegard Büning; Jessica Sallach; Ingrid Hausser; Marcela Del Río; Fernando Larcher; Rodolfo Murillas
Journal:  Mol Ther Nucleic Acids       Date:  2016-04-05       Impact factor: 10.183

View more
  23 in total

1.  Two Novel Mutations in LAMC2 Gene in Iranian Families Affected by Junctional Epidermolysis Bullosa.

Authors:  Maryam Taghdiri; Sirous Naeimi; Majid Fardaei; Seyed Mohammad Bagher Tabei
Journal:  Rep Biochem Mol Biol       Date:  2022-01

2.  Stem cells: a comprehensive review of origins and emerging clinical roles in medical practice.

Authors:  Salomon Poliwoda; Nazir Noor; Evan Downs; Amanda Schaaf; Abigail Cantwell; Latha Ganti; Alan D Kaye; Luke I Mosel; Caroline B Carroll; Omar Viswanath; Ivan Urits
Journal:  Orthop Rev (Pavia)       Date:  2022-08-25

Review 3.  Epidermolysis Bullosa: A Review of the Tissue-Engineered Skin Substitutes Used to Treat Wounds.

Authors:  Alex du Rand; John M T Hunt; Vaughan Feisst; Hilary M Sheppard
Journal:  Mol Diagn Ther       Date:  2022-10-17       Impact factor: 4.476

Review 4.  Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.

Authors:  Allison R Keith; Kirk Twaroski; Christen L Ebens; Jakub Tolar
Journal:  Expert Opin Biol Ther       Date:  2020-03-20       Impact factor: 4.388

Review 5.  Toward Combined Cell and Gene Therapy for Genodermatoses.

Authors:  Laura De Rosa; Maria Carmela Latella; Alessia Secone Seconetti; Cecilia Cattelani; Johann W Bauer; Sergio Bondanza; Michele De Luca
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-05-01       Impact factor: 10.005

6.  Genome Editing for Rare Diseases.

Authors:  Arun Pradhan; Tanya V Kalin; Vladimir V Kalinichenko
Journal:  Curr Stem Cell Rep       Date:  2020-07-07

7.  Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.

Authors:  Jose Bonafont; Angeles Mencía; Esteban Chacón-Solano; Wai Srifa; Sriram Vaidyanathan; Rosa Romano; Marta Garcia; Rosario Hervás-Salcedo; Laura Ugalde; Blanca Duarte; Matthew H Porteus; Marcela Del Rio; Fernando Larcher; Rodolfo Murillas
Journal:  Mol Ther       Date:  2021-02-18       Impact factor: 12.910

8.  Research Techniques Made Simple: Delivery of the CRISPR/Cas9 Components into Epidermal Cells.

Authors:  Huishan Shi; Jos P H Smits; Ellen H van den Bogaard; Matthew G Brewer
Journal:  J Invest Dermatol       Date:  2021-06       Impact factor: 7.590

Review 9.  Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020.

Authors:  Cristina Has; Andrew South; Jouni Uitto
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

Review 10.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.